FUSION MEDICAL TECHNOLOGIES RAPISEAL 510(k) FILED IN APRIL, FIRM SAYS IN PROSPECTUS; 96% EFFECTIVENESS RATE IN LUNG RESECTION PATIENTS SHOWN IN CLINICALS
This article was originally published in The Gray Sheet
Executive Summary
Fusion Medical Technologies' RapiSeal collagen-based biodegradable patch successfully treated 96% of air leaks in a study of cancer patients who were undergoing lung resection surgery, the Mountain View, California-based firm says in a preliminary prospectus for its initial public offering.